Ken Griffin Rezolute, Inc. Call Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding RZLT
# of Institutions
53Shares Held
39.3MCall Options Held
1KPut Options Held
0-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$55.7 Million0.12% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.99MShares$14.8 Million0.86% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.8MShares$13.8 Million1.78% of portfolio
-
Adar1 Capital Management, LLC Austin, TX2.06MShares$10.2 Million1.68% of portfolio
-
Affinity Asset Advisors, LLC New York, NY1.85MShares$9.14 Million1.08% of portfolio
About Rezolute, Inc.
- Ticker RZLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,600
- Market Cap $192M
- Description
- Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...